New Tool: ProSource
Checkout our packaging and processing solutions finder, ProSource.

FDA Approves ‘Glowing Tumor’ Imaging Drug

The drug is attracted to ovarian cancer tissue and illuminates under fluorescent light to pinpoint cancer.

Only 20% of ovarian cancers are detected early, mostly because there are seldom symptoms that don’t mimic common bladder, bowel or gastrointestinal issues. However, a recent Penn Today article noted the FDA approval of Cytalux, an imaging drug for ovarian cancer that aims to improve early detection, and therefore survival rates.

Once inside the body, the drug, also known as pafolacianine, seeks out ovarian cancer tissue and illuminates it when exposed to fluorescent light. This helps surgeons precisely locate the cancer for removal and decreased chance of recurrence after initial treatment. Penn and its industry partners have also developed targeted technologies for cancer of the lung, brain, breast, sarcoma, head and neck, and urinary tract.

How to Honor a Leader
Induction into the Packaging & Processing Hall of Fame is the highest honor in our industry. Submit your leader to be considered for the Class of 2024 now through June 10th. New members will be inducted at PACK EXPO International in Chicago.
Read More
How to Honor a Leader
Discover Our Content Hub
Access Healthcare Packaging's free educational content library!
Read More
Discover Our Content Hub